PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 8, 2025BloodOpen Access

A phase 1b trial of the EZH2 inhibitor tazemetostat combined with CAR T cell therapy in B cell lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAnna AlperovichDCDaniel ChoiSCSelina Chen‐Kiang

Discussion

Loading...

Member takes

Overview

Phase 1b trial shows tazemetostat enhances CAR T cell therapy efficacy in B cell lymphomas, suggesting better outcomes.

Key Points

  • Evaluate the combination of tazemetostat and CAR T cell therapy in patients with B cell lymphomas.
  • Single-center phase Ib clinical trial
  • Patients received tazemetostat prior to and during CAR T cell therapy
  • Endpoints included safety, feasibility, and response rates
  • 100% overall response rate among patients
  • 77% achieved complete response, especially in FL
  • 54% maintained progression-free survival at 11 months follow-up

Cite This Study

Alperovich et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3a7https://doi.org/10.1182/blood-2025-1011
View Full Paper
Ask AI
Bookmark
Share